Showing results (61-70 of 435) with videos related to

Sort By:
Pageof 44
British Journal of Haematology|August 3, 2006
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolismFrancesca Elice, Louis Fink, Guido Tricot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2012
Cure models as a useful statistical tool for analyzing survivalMegan Othus, Bart Barlogie, Michael L Leblanc, et al.
Bone|February 26, 2008
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myelomaYa-Wei Qiang, Bart Barlogie, Stuart Rudikoff, et al.
British Journal of Haematology|December 13, 2006
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseMauricio Pineda-Roman, Vanessa Bolejack, Varant Arzoumanian, et al.
Blood|May 16, 2009
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaTwyla B Bartel, Jeff Haessler, Tracy L Y Brown, et al.
Blood Cancer Journal|July 8, 2018
Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trialsSikander Ailawadhi, Susanna Jacobus, Rachael Sexton, et al.
Haematologica|June 12, 2025
Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu miceWen Ling, Maurizio Zangari, Frits Van Rhee, et al.
Blood|April 10, 2007
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisFrits van Rhee, Vanessa Bolejack, Klaus Hollmig, et al.
Clinical Advances in Hematology & Oncology : H&O|September 25, 2010
Castleman disease in the 21st century: an update on diagnosis, assessment, and therapyFrits van Rhee, Katie Stone, Susann Szmania, et al.
Blood|April 20, 2002
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapyYue-Jin Wen, Rui Min, Guido Tricot, et al.
Pageof 44